The Journal of Allergy and Clinical Immunology
Volume 124, Issue 2 , Pages 286-291.e6 , August 2009

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

  • Alison M. Hofmann, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Amy M. Scurlock, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas, Little Rock, Ark
    • ,
  • Stacie M. Jones, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas, Little Rock, Ark
    • ,
  • Kricia P. Palmer, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas, Little Rock, Ark
    • ,
  • Yuliya Lokhnygina, PhD

      Affiliations

    • Department of Biostatistics and Bioinformatics, Duke University, Durham, NC
    • ,
  • Pamela H. Steele, CPNP

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • Janet Kamilaris, RN

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • ,
  • A. Wesley Burks, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Wesley Burks, MD, Division of Allergy and Immunology, Duke University Medical Center, Box 2644, Durham, NC 27710.

Received 14 October 2008 ,Revised 30 March 2009 ,Accepted 31 March 2009.

  • Image Result

    Estimated risk of specific symptoms during the initial escalation day. Symptoms were recorded during the initial escalation day in 4 categories: upper respiratory tract, skin, abdominal, and chest.

    Estimated risk of specific symptoms during the initial escalation day. Symptoms were recorded during the initial escalation day in 4 categories: upper respiratory tract, skin, abdominal, and chest.

  • Image Result

    Estimated risk of specific symptoms during the buildup phase. Symptoms were recorded during the buildup phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.

    Estimated risk of specific symptoms during the buildup phase. Symptoms were recorded during the buildup phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.

  • Image Result

    Estimated risk of specific symptoms during the home dosing phase. Symptoms were recorded during the home dosing phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.

    Estimated risk of specific symptoms during the home dosing phase. Symptoms were recorded during the home dosing phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.

  • Image Result

    Symptom scoring sheet for desensitization and dosage escalations. This figure is the description of the symptom classification of mild, moderate, and severe used by trained personnel and parents for r

    Symptom scoring sheet for desensitization and dosage escalations. This figure is the description of the symptom classification of mild, moderate, and severe used by trained personnel and parents for recording symptoms during desensitizations, dose escalations, and home dosings.

 Supported by the Food Allergy and Anaphylaxis Network, the Gerber Foundation, the Food Allergy Project, and the Dorothy and Frank Robins Family Foundation. The project described was supported by grant no. 1 UL1 RR024128-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.

 Disclosure of potential conflict of interest: A. M. Hofmann has received research support from the Pediatric Scientist Development Program. A. M. Scurlock has received research support from Genocea Biosciences and NIH. S. M. Jones has received research support from the National Peanut Board, the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Dyax Corp and is on the Medical Advisory Board for the Food Allergy and Anaphylaxis Network. A. W. Burks is a consultant for ActoGeniX NV, Novartis, McNeil Nutritionals, and Mead Johnson; is a minority stockholder with Allertein and MastCell, Inc; is on the Advisory Board of Dannon Co Probiotics; is on the speakers' bureau for EpiPen/Dey, LP; is on the Data Monitoring Committee for Genentech; is on the Expert Panel for Nutricia; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, Gerber, and Mead Johnson; has provided legal consultation regarding food allergy; is on the Medical Board of Directors for the Food Allergy and Anaphylaxis Network; is a Dermatological Allergy Committee member of the American College of Allergy, Asthma & Immunology; is a study section member at the National Institutes of Health Hypersensitivity, Autoimmune, Immune-mediated Diseases; and is on the Journal of Allergy and Clinical Immunology reviewer board. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00556-9

doi: 10.1016/j.jaci.2009.03.045

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 2 , Pages 286-291.e6 , August 2009

Article Tools

* Image Usage & Resolution